COMMUNIQUÉS West-GlobeNewswire

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
12/05/2026
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW [...]
Blue Point Brewing Launches Magic Hour IPA—A Bright, Tropical 6% ABV Sipper for Golden Hour
12/05/2026
New year-round American IPA balances hop-forward flavor with easy drinkability—available on draft and in 6-pack 12oz cans across NY, CT, PA & NJ PATCHOGUE, N.Y., May 12, 2026 (GLOBE NEWSWIRE) -- Blue Point Brewing [...]
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
12/05/2026
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase [...]
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
12/05/2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced [...]
Compass Therapeutics to Participate in Upcoming May Investor Events
12/05/2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human [...]
ProQR Announces First Quarter 2026 Operating and Financial Results
12/05/2026
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the [...]
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
12/05/2026
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and [...]
Aveanna to Participate at the William Blair 46th Annual Growth Stock Conference
12/05/2026
ATLANTA, May 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the William Blair 46 th Annual Growth Stock Conference in [...]
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
12/05/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s EBD TM ( [...]
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
12/05/2026
Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter [...]
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
12/05/2026
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
Sionna Therapeutics Reports First Quarter 2026 Financial Results
12/05/2026
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of [...]
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
12/05/2026
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that [...]
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
12/05/2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineering Findings [...]
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
12/05/2026
Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
12/05/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection [...]
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
12/05/2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual [...]
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]

Pages